Evaluation of amyloid protective factors and alzheimer disease neurodegeneration protective factors in elderly individuals

JAMA Neurology

Volumn 74, Issue 6, 2017, Pages 718-726

  Vemuri, Prashanthi ^a   Knopman, David S ^a   Lesnick, Timothy G ^a   Przybelski, Scott A ^a   Mielke, Michelle M ^a   Graff Radford, Jonathan ^a   Murray, Melissa E ^b   Roberts, Rosebud O ^a   Vassilaki, Maria ^a   Lowe, Val J ^a   Machulda, Mary M ^a   Jones, David T ^a   Petersen, Ronald C ^a   Jack, Clifford R ^a  

^a MAYO CLINIC ROCHESTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PROTEIN; APOLIPOPROTEIN E; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; AMYLOID BETA PROTEIN; ANILINE DERIVATIVE; THIAZOLE DERIVATIVE;

AGE; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; COHORT ANALYSIS; DEMOGRAPHY; DIABETES MELLITUS; DYSLIPIDEMIA; GENOTYPE; HEART DISEASE; HUMAN; HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; METABOLIC DISORDER; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PHYSICAL INACTIVITY; POPULATION RESEARCH; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SMOKING; DEGENERATIVE DISEASE; DIAGNOSTIC IMAGING; FEMALE; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTECTION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEURODEGENERATIVE DISEASES; POSITRON-EMISSION TOMOGRAPHY; PROTECTIVE FACTORS; RISK FACTORS; THIAZOLES;

EID: 85020695128     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2017.0244     Document Type: Article

References (67)

1. Ingelsson M, Fukumoto H, Newell KL, et al. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology. 2004;62(6):925-931.
2. Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-216.
3. Scacchi R, De Bernardini L, Mantuano E, Donini LM, Vilardo T, Corbo RM. Apolipoprotein E (APOE) allele frequencies in late-onset sporadic Alzheimer's disease (AD), mixed dementia and vascular dementia: lack of association of epsilon 4 allele with AD in Italian octogenarian patients. Neurosci Lett. 1995;201(3):231-234.
4. Sobel E, Louhija J, Sulkava R, et al. Lack of association of apolipoprotein E allele epsilon 4 with late-onset Alzheimer's disease among Finnish centenarians. Neurology. 1995;45(5):903-907.
5. Farrer LA, Cupples LA, Haines JL, et al; APOE and Alzheimer Disease Meta Analysis Consortium. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. a meta-analysis. JAMA. 1997;278(16):1349-1356.
6. Nelson PT, Head E, Schmitt FA, et al. Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies. Acta Neuropathol. 2011;121(5):571-587.
7. Jack CR Jr, Wiste HJ, Weigand SD, et al. Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. Lancet Neurol. 2014;13(10):997-1005.
8. Vemuri P, Knopman DS. The role of cerebrovascular disease when there is concomitant Alzheimer disease. Biochim Biophys Acta. 2015;1862(5):952-956.
9. Jansen WJ, Ossenkoppele R, Knol DL, et al; Amyloid Biomarker Study Group. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924-1938.
10. Jack CR Jr, Wiste HJ, Weigand SD, et al. Age, sex, and APOE ε4 effects on memory, brain structure, and β-amyloid across the adult life span. JAMA Neurol. 2015;72(5):511-519.
11. Wilson RS, Boyle PA, Yu L, Barnes LL, Schneider JA, Bennett DA. Life-span cognitive activity, neuropathologic burden, and cognitive aging. Neurology. 2013;81(4):314-321.
12. Vemuri P, Lesnick TG, Przybelski SA, et al. Association of lifetime intellectual enrichment with cognitive decline in the older population. JAMA Neurol. 2014;71(8):1017-1024.
13. Luchsinger JA, Tang M-X, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol. 2001;154(7):635-641.
14. Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch Neurol. 2009;66(3):300-305.
15. Kivipelto M, Ngandu T, Fratiglioni L, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol. 2005;62(10):1556-1560.
16. Zhong G, Wang Y, Zhang Y, Guo JJ, Zhao Y. Smoking is associated with an increased risk of dementia: a meta-analysis of prospective cohort studies with investigation of potential effect modifiers. PLoS One. 2015;10(3):e0118333.
17. Akinyemi RO, Mukaetova-Ladinska EB, Attems J, Ihara M, Kalaria RN. Vascular risk factors and neurodegeneration in ageing related dementias: Alzheimer's disease and vascular dementia. Curr Alzheimer Res. 2013;10(6):642-653.
18. Enzinger C, Fazekas F, Matthews PM, et al. Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects. Neurology. 2005;64(10):1704-1711.
19. Roberts RO, Knopman DS, Cha RH, et al. Diabetes and elevated hemoglobin A1c levels are associated with brain hypometabolism but not amyloid accumulation. J Nucl Med. 2014;55(5):759-764.
20. Vassilaki M, Aakre JA, Cha RH, et al. Multimorbidity and risk of mild cognitive impairment. J Am Geriatr Soc. 2015;63(9):1783-1790.
21. Vassilaki M, Aakre JA, Mielke MM, et al. Multimorbidity and neuroimaging biomarkers among cognitively normal persons. Neurology. 2016;86(22):2077-2084.
22. Rocca WA, Yawn BP, St Sauver JL, Grossardt BR, Melton LJ III. History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. Mayo Clin Proc. 2012;87(12):1202-1213.
23. St Sauver JL, Grossardt BR, Leibson CL, Yawn BP, Melton LJ III, Rocca WA. Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project. Mayo Clin Proc. 2012;87(2):151-160.
24. St Sauver JL, Grossardt BR, Yawn BP, et al. Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system. Int J Epidemiol. 2012;41(6):1614-1624.
25. St Sauver JL, Grossardt BR, Yawn BP, Melton LJ III, Rocca WA. Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester epidemiology project. Am J Epidemiol. 2011;173(9):1059-1068.
26. Petersen RC, Roberts RO, Knopman DS, et al; The Mayo Clinic Study of Aging. Prevalence of mild cognitive impairment is higher in men. Neurology. 2010;75(10):889-897.
27. Roberts RO, Geda YE, Knopman DS, et al. The incidence of MCI differs by subtype and is higher in men: the Mayo Clinic Study of Aging. Neurology. 2012;78(5):342-351.
28. Vemuri P, Lesnick TG, Przybelski SA, et al. Effect of lifestyle activities on Alzheimer disease biomarkers and cognition. Ann Neurol. 2012;72(5):730-738.
29. Geda YE, Topazian HM, Roberts LA, et al. Engaging in cognitive activities, aging, and mild cognitive impairment: a population-based study. J Neuropsychiatry Clin Neurosci. 2011;23(2):149-154.
30. Roberts RO, Knopman DS, Przybelski SA, et al. Association of type 2 diabetes with brain atrophy and cognitive impairment. Neurology. 2014;82(13):1132-1141.
31. Lowe VJ, Kemp BJ, Jack CR Jr, et al. Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med. 2009;50(6):878-886.
32. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain. 2008;131(Pt 3):665-680.
33. Senjem ML, Lowe V, Kemp B, et al. Automated ROI analysis of 11C Pittsburgh compound B images using structural magnetic resonance imaging atlases, Alzheimer's and Dementia. Paper presented at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease.
34. Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46(12):1959-1972.
35. Jack CR Jr, Wiste HJ, Weigand SD, et al. Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. Brain. 2015;138(Pt 12):3747-3759.
36. Villemagne VL, Burnham S, Bourgeat P, et al; Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357-367.
37. Sojkova J, Zhou Y, An Y, et al. Longitudinal patterns of β-amyloid deposition in nondemented older adults. Arch Neurol. 2011;68(5):644-649.
38. Corder EH, Ghebremedhin E, Taylor MG, Thal DR, Ohm TG, Braak H. The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex, and APOE polymorphism. Ann N Y Acad Sci. 2004;1019:24-28.
39. Mielke MM, Vemuri P, Rocca WA. Clinical epidemiology of Alzheimer's disease: assessing sex and gender differences. Clin Epidemiol. 2014;6:37-48.
40. Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A. 2001;98(10):5856-5861.
41. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A. 1998;95(11):6460-6464.
42. Reitz C. Dyslipidemia and dementia: current epidemiology, genetic evidence, and mechanisms behind the associations. J Alzheimers Dis. 2012;30(suppl 2):S127-S145.
43. Kivipelto M, Helkala EL, Laakso MP, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med. 2002;137(3):149-155.
44. Willette AA, Johnson SC, Birdsill AC, et al. Insulin resistance predicts brain amyloid deposition in late middle-aged adults. Alzheimers Dement. 2015;11(5):504-510.e1, e1.
45. Thambisetty M, Jeffrey Metter E, Yang A, et al. Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore Longitudinal Study of Aging. JAMA Neurol. 2013;70(9):1167-1172.
46. Fjell AM, McEvoy L, Holland D, Dale AM, Walhovd KB; Alzheimer's Disease Neuroimaging Initiative. What is normal in normal aging? effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus. Prog Neurobiol. 2014;117:20-40.
47. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67(1):122-131.
48. Vemuri P, Wiste HJ, Weigand SD, et al; Alzheimer's Disease Neuroimaging Initiative. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol. 2010;67(3):308-316.
49. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259.
50. Jack CR Jr, Knopman DS, Weigand SD, et al. An operational approach to NIA-AA criteria for preclinical Alzheimer's disease. Ann Neurol. 2012;71(6):765-775.
51. Knopman DS, Jack CR Jr, Wiste HJ, et al. Brain injury biomarkers are not dependent on β-amyloid in normal elderly. Ann Neurol. 2013;73(4):472-480.
52. Vemuri P, Lesnick TG, Przybelski SA, et al. Effect of intellectual enrichment on AD biomarker trajectories: longitudinal imaging study. Neurology. 2016;86(12):1128-1135.
53. Dosunmu R, Wu J, Adwan L, et al. Lifespan profiles of Alzheimer's disease-associated genes and products in monkeys and mice. J Alzheimers Dis. 2009;18(1):211-230.
54. Elcoroaristizabal Martín X, Gómez Busto F, Artaza Artabe I, et al. Genetic profiles of longevity and healthy cognitive aging in nonagenarians from the Basque Country. Rev Esp Geriatr Gerontol. 2011;46(4):217-222.
55. Sebastiani P, Bae H, Sun FX, et al. Meta-analysis of genetic variants associated with human exceptional longevity. Aging (Albany NY). 2013;5(9):653-661.
56. Suri S, Heise V, Trachtenberg AJ, Mackay CE. The forgotten APOE allele: a review of the evidence and suggested mechanisms for the protective effect of APOE ε2. Neurosci Biobehav Rev. 2013;37(10 Pt 2):2878-2886.
57. Bennett DA, Arnold SE, Valenzuela MJ, Brayne C, Schneider JA. Cognitive and social lifestyle: links with neuropathology and cognition in late life. Acta Neuropathol. 2014;127(1):137-150.
58. Elwood P, Galante J, Pickering J, et al. Healthy lifestyles reduce the incidence of chronic diseases and dementia: evidence from the Caerphilly cohort study. PLoS One. 2013;8(12):e81877.
59. Landau SM, Marks SM, Mormino EC, et al. Association of lifetime cognitive engagement and low β-amyloid deposition. Arch Neurol. 2012;69(5):623-629.
60. Mattson MP. Lifelong brain health is a lifelong challenge: from evolutionary principles to empirical evidence. Ageing Res Rev. 2015;20:37-45.
61. Norton MC, Dew J, Smith H, et al; Cache County Investigators. Lifestyle behavior pattern is associated with different levels of risk for incident dementia and Alzheimer's disease: the Cache County study. J Am Geriatr Soc. 2012;60(3):405-412.
62. Schneider N, Yvon C. A review of multidomain interventions to support healthy cognitive ageing. J Nutr Health Aging. 2013;17(3):252-257.
63. Small GW, Siddarth P, Ercoli LM, Chen ST, Merrill DA, Torres-Gil F. Healthy behavior and memory self-reports in young, middle-aged, and older adults. Int Psychogeriatr. 2013;25(6):981-989.
64. Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP, Breitner JC; Cache County Study Investigators. Apolipoprotein E ε4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: the Cache County Study. Arch Gen Psychiatry. 2004;61(5):518-524.
65. Satizabal CL, Beiser AS, Chouraki V, Chêne G, Dufouil C, Seshadri S. Incidence of dementia over three decades in the Framingham Heart Study. N Engl J Med. 2016;374(6):523-532.
66. Kövari E, Herrmann FR, Bouras C, Gold G. Amyloid deposition is decreasing in aging brains: an autopsy study of 1599 older people. Neurology. 2014;82(4):326-331.
67. Whitwell JL, Josephs KA, Murray ME, et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology. 2008;71(10):743-749.